secwatch.observer — SEC 8-K summary
======================================

Issuer:     VACCINEX, INC. (VCNX)
CIK:        0001205922
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001193125-23-065339
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaccinex enrolls 36 patients in KEYNOTE-B84 HNSCC study; interim analysis due mid-2023
--------------------------------------------------------------------------------

- Phase 1b/2 trial evaluating pepinemab + KEYTRUDA in recurrent/metastatic HNSCC.
- Enrollment of 36 subjects triggers pre-planned interim analysis; results expected mid-2023.
- Primary endpoints: safety (TEAEs) and objective response rate (ORR).
- Company notes improved durable responses in PD-L1 low (CPS<20) patient subset.
- Full study plans to enroll ~62 patients; pepinemab global rights held by Vaccinex.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1205922/000119312523065339/0001193125-23-065339-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1205922/000119312523065339/d471144d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-065339

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer